Journal of Neuro-Oncology

, Volume 120, Issue 2, pp 347–352 | Cite as

Venous thromboembolism in high grade glioma among surgical patients: results from a single center over a 10 year period

  • Timothy R. Smith
  • Rishi R. Lall
  • Randall B. Graham
  • Jamal McclendonJr.
  • Rohan R. Lall
  • Allan D. Nanney
  • Joseph G. Adel
  • Anaadriana Zakarija
  • James P. Chandler
Clinical Study


Patients with high-grade glioma are at elevated risk of venous thromboembolism (VTE). The relationship between VTE and survival in glioma patients remains unclear, as does the optimal protocol for chemoprophylaxis. The purpose of this study was to assessthe incidence of and risk factors associated with VTE in patients with high-grade glioma, and the correlation between VTE and survival in this population. Furthermore, we sought to define a protocol for perioperative DVT prophylaxis. This was a retrospective review of patients who underwent craniotomy for resection of high-grade glioma (WHO grade III or IV) at Northwestern University between 1999 and 2010. A total of 336 patients met inclusion criteria. 53 patients developed postoperative VTE (15.7 %). Median survival was 12.0 months and was not significantly different between VTE(+) and VTE(−) patients. Demographics and surgical factors were not significantly correlated with VTE development. Prior history of VTE was highly predictive of postoperative VTE (OR 7.1, p < .01), as was seizure (OR 2.4, p = .005). Increased duration of postoperative ICU stay was also a risk factor for VTE (p = .025). 25 patients in our study received prophylactic anticoagulation(pAC) with either heparin or enoxaparin. Early initiation of pAC was associated with decreased incidence of VTE (p = .042). There were no hemorrhagic complications in patients receiving pAC. VTE is a common complication in high-grade glioma patients. Early initiation of anticoagulation is safe and may decrease the risk of VTE. We recommend initiation of chemoprophylaxis on postoperative day 1 in patients without contraindication.


Venous thromboembolism Glioma High-grade glioma Glioblastoma Deep venous thrombosis Pulmonary embolism Anticoagulation 


Conflicts of Interest

The authors have no financial disclosures or conflicts of interest to report.


  1. 1.
    Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D’Angelo A et al (1998) Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339:80–85PubMedCrossRefGoogle Scholar
  2. 2.
    Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268–1279PubMedCrossRefGoogle Scholar
  3. 3.
    Bastida E, Ordinas A, Escolar G, Jamieson GA (1984) Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. Blood 64:177–184PubMedGoogle Scholar
  4. 4.
    Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F et al (1997) Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 33:1592–1596PubMedCrossRefGoogle Scholar
  5. 5.
    Cerrato D, Ariano C, Fiacchino F (1978) Deep vein thrombosis and low-dose heparin prophylaxis in neurosurgical patients. J Neurosurg 49:378–381PubMedCrossRefGoogle Scholar
  6. 6.
    Chiocca EA, Schwartzbaum JA (2007) Gliomas and venous thromboembolism: how common? J Neurosurg 106:599–600 discussion 600, 2007 PubMedCrossRefGoogle Scholar
  7. 7.
    Constantini S, Kanner A, Friedman A, Shoshan Y, Israel Z, Ashkenazi E et al (2001) Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 94:918–921PubMedCrossRefGoogle Scholar
  8. 8.
    Dhami MS, Bona RD, Calogero JA, Hellman RM (1993) Venous thromboembolism and high grade gliomas. Thromb Haemost 70:393–396PubMedGoogle Scholar
  9. 9.
    Dickinson LD, Miller LD, Patel CP, Gupta SK (1998) Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 43:1074–1081PubMedCrossRefGoogle Scholar
  10. 10.
    Jenkins EO, Schiff D, Mackman N, Key NS (2010) Venous thromboembolism in malignant gliomas. J Thromb Haemost 8:221–227PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Lip GY, Chin BS, Blann AD (2002) Cancer and the prothrombotic state. Lancet Oncol 3:27–34PubMedCrossRefGoogle Scholar
  12. 12.
    Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89:640–646PubMedCrossRefGoogle Scholar
  13. 13.
    Pan E, Tsai JS, Mitchell SB (2009) Retrospective study of venous thromboembolic and intracerebral hemorrhagic events in glioblastoma patients. Anticancer Res 29:4309–4313PubMedGoogle Scholar
  14. 14.
    Perry JR (2012) Thromboembolic disease in patients with high-grade glioma. Neuro Oncol 14(Suppl 4):iv73–iv80PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8:1959–1965PubMedCrossRefGoogle Scholar
  16. 16.
    Sciacca FL, Ciusani E, Silvani A, Corsini E, Frigerio S, Pogliani S et al (2004) Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res 10:1312–1317PubMedCrossRefGoogle Scholar
  17. 17.
    Semrad TJ, O’Donnell R, Wun T, Chew H, Harvey D, Zhou H et al (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106:601–608PubMedCrossRefGoogle Scholar
  18. 18.
    Silvani A, Gaviani P, Lamperti E, Botturi A, Ferrari D, Simonetti G et al (2011) Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients. Neurol Sci 32(Suppl 2):S229–S231PubMedCrossRefGoogle Scholar
  19. 19.
    Simanek R, Vormittag R, Hassler M, Roessler K, Schwarz M, Zielinski C et al (2007) Venous thromboembolism and survival in patients with high-grade glioma. Neuro Oncol 9:89–95PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Smith SF, Biggs MT, Sekhon LH (2005) Risk factors and prophylaxis for deep venous thrombosis in neurosurgery. Surg Technol Int 14:69–76PubMedGoogle Scholar
  21. 21.
    Sonaglia F, Agnelli G, Baroni M, Severi P, Quintavalla R, D’Angelo SV (1999) Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. Blood Coagul Fibrinolysis 10:459–463PubMedCrossRefGoogle Scholar
  22. 22.
    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343:1846–1850PubMedCrossRefGoogle Scholar
  23. 23.
    Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG (2004) ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 100:1717–1723PubMedCrossRefGoogle Scholar
  24. 24.
    Treasure T, Hill J (2010) NICE guidance on reducing the risk of venous thromboembolism in patients admitted to hospital. J R Soc Med 103:210–212PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Walker AJ, Card TR, West J, Crooks C, Grainge MJ (2012) Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 49:1404–1413PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Timothy R. Smith
    • 1
  • Rishi R. Lall
    • 1
  • Randall B. Graham
    • 1
  • Jamal McclendonJr.
    • 1
  • Rohan R. Lall
    • 1
  • Allan D. Nanney
    • 1
  • Joseph G. Adel
    • 1
  • Anaadriana Zakarija
    • 2
  • James P. Chandler
    • 1
    • 3
  1. 1.Department of Neurological SurgeryNorthwestern University, McGaw Medical CenterChicagoUSA
  2. 2.Department of HematologyNorthwestern University, McGaw Medical CenterChicagoUSA
  3. 3.Department of Neurological SurgeryNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations